Quoin Pharmaceuticals（QNRX）株式概要クオイン・ファーマシューティカルズ社は、後期専門製薬会社で、米国における希少・希少疾患の治療薬の開発と商業化に注力している。 詳細QNRX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( $0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない 意味のある時価総額がありません ( $11M )+1 さらなるリスクすべてのリスクチェックを見るQNRX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$6.48該当なし内在価値ディスカウントEst. Revenue$PastFuture-21m92016201920222025202620282031Revenue US$8.6Earnings US$1.5AdvancedSet Fair ValueView all narrativesGANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.1% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2225428d agoQuoin Pharmaceuticals, Ltd. 競合他社bioAffinity TechnologiesSymbol: NasdaqCM:BIAFMarket cap: US$10.9mAprea TherapeuticsSymbol: NasdaqCM:APREMarket cap: US$9.4mImunonSymbol: NasdaqCM:IMNNMarket cap: US$10.5mBioVieSymbol: NasdaqCM:BIVIMarket cap: US$11.9m価格と性能株価の高値、安値、推移の概要Quoin Pharmaceuticals過去の株価現在の株価US$6.4852週高値US$41.8052週安値US$5.20ベータ1.821ヶ月の変化-1.82%3ヶ月変化-10.19%1年変化-1.89%3年間の変化-96.77%5年間の変化n/aIPOからの変化-99.90%最新ニュースQuoin Pharmaceuticals, Ltd. to Report Q1, 2026 Results on May 07, 2026Apr 30+ 1 more updateNew major risk - Market cap size Apr 28New major risk - Negative shareholders equity Mar 30No longer forecast to breakeven Mar 27Quoin Pharmaceuticals Ltd. Provides Clinical and Regulatory Update for Qrx003 in Netherton SyndromeMar 27New minor risk - Profitability Mar 26最新情報をもっと見るRecent updatesQuoin Pharmaceuticals, Ltd. to Report Q1, 2026 Results on May 07, 2026Apr 30+ 1 more updateNew major risk - Market cap size Apr 28New major risk - Negative shareholders equity Mar 30No longer forecast to breakeven Mar 27Quoin Pharmaceuticals Ltd. Provides Clinical and Regulatory Update for Qrx003 in Netherton SyndromeMar 27New minor risk - Profitability Mar 26Quoin Pharmaceuticals, Ltd. to Report Q4, 2025 Results on Mar 26, 2026Mar 19Quoin Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation For QRX003 For The Treatment Of Netherton SyndromeMar 12Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton SyndromeJan 28Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003Jan 21Forecast to breakeven in 2028 Dec 31Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery TechnologiesNov 12New major risk - Negative shareholders equity Nov 09Quoin Pharmaceuticals, Ltd. to Report Q3, 2025 Results on Nov 06, 2025Oct 30+ 1 more updateQuoin Pharmaceuticals, Ltd. announced that it has received $16.450005 million in funding from a group of investorsOct 24New major risk - Share price stability Oct 10Quoin Pharmaceuticals, Ltd. announced that it expects to receive $16.450005 million in funding from a group of investorsOct 10Quoin Pharmaceuticals Ltd. Appoints Sally Lawlor as Chief Financial Officer, Effective August 18, 2025Aug 18Price target decreased by 68% to US$48.50 Aug 11Price target increased by 40% to US$210 Aug 10Quoin Pharmaceuticals, Ltd. to Report Q2, 2025 Results on Aug 07, 2025Jul 31Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon DunnJul 10Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin DiseasesJun 27Quoin Pharmaceuticals, Ltd., Annual General Meeting, Aug 21, 2025Jun 25+ 1 more updatePrice target increased by 34% to US$210 Jun 02Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical StudyMay 22Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 15Quoin Pharmaceuticals, Ltd. to Report Q1, 2025 Results on May 13, 2025May 06Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric PatientApr 02Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMar 25No longer forecast to breakeven Mar 14New minor risk - Profitability Mar 13Quoin Pharmaceuticals, Ltd. to Report Q4, 2024 Results on Mar 13, 2025Mar 06Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease IndicationsMar 04Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFeb 27Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton SyndromeJan 23Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical StudyJan 06Forecast to breakeven in 2027 Dec 31Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical StudyDec 19Quoin Pharmaceuticals, Ltd. Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical StudiesDec 18Quoin Pharmaceuticals, Ltd. has filed a Follow-on Equity Offering.Dec 12Price target increased by 25% to US$6.00 Nov 13New major risk - Financial position Nov 10Quoin Pharmaceuticals Ltd. Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome PatientNov 05Quoin Pharmaceuticals, Ltd. to Report Q3, 2024 Results on Nov 07, 2024Nov 01+ 1 more updateQuoin Pharmaceuticals, Ltd., Annual General Meeting, Dec 05, 2024Oct 01Price target decreased by 17% to US$4.82 Aug 09Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin SyndromeAug 06Quoin Pharmaceuticals, Ltd. to Report Q2, 2024 Results on Aug 08, 2024Aug 02Quoin Pharmaceuticals, Ltd. Announces International Expansion of Ongoing Clinical Trials for Netherton SyndromeJun 28New minor risk - Profitability Jun 12Quoin Pharmaceuticals Receives Written Notice from Nasdaq Regarding Non- Compliance Minimum Bid Price Requirement Per ADS as Required by Nasdaq Listing Rule 5550(a)(2)May 04Quoin Pharmaceuticals, Ltd. to Report Q1, 2024 Results on May 09, 2024May 03New minor risk - Profitability Mar 14Quoin Pharmaceuticals, Ltd. to Report Q4, 2023 Results on Mar 13, 2024Mar 08Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical StudiesMar 05Quoin Pharmaceuticals, Ltd. has filed a Follow-on Equity Offering.Feb 13Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination ProductFeb 09Forecast to breakeven in 2026 Dec 31Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeDec 21New minor risk - Profitability Nov 16Quoin Pharmaceuticals, Ltd. to Report Q3, 2023 Results on Nov 08, 2023Nov 04Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton SyndromeOct 25Price target decreased by 13% to US$90.31 Oct 04Quoin Pharmaceuticals, Ltd., Annual General Meeting, Oct 19, 2023Sep 13Quoin Pharmaceuticals, Ltd. to Report Q2, 2023 Results on Aug 02, 2023Jul 29New major risk - Share price stability Jul 23Price target increased by 37% to US$12.00 May 10No longer forecast to breakeven Mar 16Price target decreased by 13% to US$10.40 Mar 05Forecast to breakeven in 2025 Dec 31High number of new and inexperienced directors Nov 16Quoin stock soars 22% on plans to start 2nd trial of QRX003 for rare skin disorder Oct 18No longer forecast to breakeven Aug 23Quoin Pharmaceuticals GAAP EPS of -$3.24 Aug 18Quoin Pharmaceuticals plunges on pricing $16.8M upsized stock offering Aug 05Forecast to breakeven in 2024 May 07High number of new and inexperienced directors Apr 27No independent directors Nov 01株主還元QNRXUS BiotechsUS 市場7D13.1%-2.2%0.6%1Y-1.9%30.4%28.7%株主還元を見る業界別リターン: QNRX過去 1 年間で30.4 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: QNRXは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is QNRX's price volatile compared to industry and market?QNRX volatilityQNRX Average Weekly Movement13.7%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.3%安定した株価: QNRXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: QNRXの 週次ボラティリティ は過去 1 年間で27%から14%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20184Michael Myersquoinpharma.comクオイン・ファーマシューティカルズ社は、後発のスペシャリティファーマであり、米国において希少疾病および希少疾病の治療薬の開発と商業化に注力している。同社の主力製品は局所ローションQRX003で、ネザートン症候群（NS）の治療薬としてフェーズ2、ピーリングスキン症候群の治療薬としてフェーズ1、SAM症候群と魚鱗癬の治療薬として前臨床段階にある。また、前臨床段階にある強皮症の治療薬QRX008、小嚢胞性リンパ奇形、静脈奇形、血管線維腫などの治療薬QRX009も開発している。クイーンズランド工科大学と研究契約を結んでいる。Quoin Pharmaceuticals, Ltd.は2018年に設立され、バージニア州アッシュバーンに拠点を置く。Quoin Pharmaceuticals, Ltd.はSkinvisible, Inc.の子会社である。もっと見るQuoin Pharmaceuticals, Ltd. 基礎のまとめQuoin Pharmaceuticals の収益と売上を時価総額と比較するとどうか。QNRX 基礎統計学時価総額US$10.70m収益（TTM）-US$15.80m売上高(TTM)n/a0.0xP/Sレシオ-0.7xPER（株価収益率QNRX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計QNRX 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$15.80m収益-US$15.80m直近の収益報告Dec 31, 2025次回決算日May 07, 2026一株当たり利益（EPS）-8.76グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率17.7%QNRX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/30 15:12終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Quoin Pharmaceuticals, Ltd. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関James MolloyAlliance Global PartnersJason ButlerCitizens JMP Securities, LLCJason McCarthyMaxim Group2 その他のアナリストを表示
GANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.1% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2225428d ago
Quoin Pharmaceuticals Ltd. Provides Clinical and Regulatory Update for Qrx003 in Netherton SyndromeMar 27
Quoin Pharmaceuticals Ltd. Provides Clinical and Regulatory Update for Qrx003 in Netherton SyndromeMar 27
Quoin Pharmaceuticals Ltd. Announces FDA Grants Fast Track Designation For QRX003 For The Treatment Of Netherton SyndromeMar 12
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton SyndromeJan 28
Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003Jan 21
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery TechnologiesNov 12
Quoin Pharmaceuticals, Ltd. announced that it has received $16.450005 million in funding from a group of investorsOct 24
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $16.450005 million in funding from a group of investorsOct 10
Quoin Pharmaceuticals Ltd. Appoints Sally Lawlor as Chief Financial Officer, Effective August 18, 2025Aug 18
Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin DiseasesJun 27
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical StudyMay 22
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 15
Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric PatientApr 02
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMar 25
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease IndicationsMar 04
Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome StudyFeb 27
Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton SyndromeJan 23
Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical StudyJan 06
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical StudyDec 19
Quoin Pharmaceuticals, Ltd. Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical StudiesDec 18
Quoin Pharmaceuticals Ltd. Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome PatientNov 05
Quoin Pharmaceuticals, Ltd. Announces International Expansion of Ongoing Clinical Trials for Netherton SyndromeJun 28
Quoin Pharmaceuticals Receives Written Notice from Nasdaq Regarding Non- Compliance Minimum Bid Price Requirement Per ADS as Required by Nasdaq Listing Rule 5550(a)(2)May 04
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical StudiesMar 05
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination ProductFeb 09
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton SyndromeDec 21
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton SyndromeOct 25
